The Board of Directors at Fortis Healthcare has given its approval for a significant scheme of arrangement. This plan involves the intra-group restructuring of its wholly owned subsidiaries, including Agilus PathLabs Private Limited and DDRC Agilus PathLabs Limited. The restructuring will be carried out by way of a scheme of arrangement under the Companies Act, subject to necessary approvals from regulatory authorities.
Fortis Healthcare Board Approves Restructuring Scheme
In a significant move for its corporate structure, the Board of Directors at Fortis Healthcare Limited has officially approved a comprehensive scheme of arrangement. This pivotal decision, made on August 5, 2026, is set to facilitate a major intra-group restructuring initiative. The primary objective of this restructuring is to streamline operations and potentially enhance corporate efficiency across its subsidiaries.
Details of the Restructuring Plan
The approved scheme will involve the consolidation and reorganization of Fortis Healthcare’s wholly owned subsidiaries. Key entities involved include Agilus PathLabs Private Limited and DDRC Agilus PathLabs Limited. The restructuring is designed to unify these entities under a more streamlined management structure, potentially leading to greater operational synergies and a clearer strategic direction for the diagnostic and healthcare services segments. The company has stated that the scheme will be executed by way of a scheme of arrangement, a legal process requiring adherence to strict regulatory guidelines.
Regulatory and Shareholder Approvals Pending
The implementation of this scheme is contingent upon securing the necessary approvals from various regulatory bodies, including the National Company Law Tribunals (NCLTs). The company anticipates that further shareholder and creditor approvals may also be required as part of the process. Fortis Healthcare has assured that the consideration for this restructuring will be subject to the terms and conditions stipulated within the scheme itself, and further details will be provided as the process moves forward.
Source: BSE
